[Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2004].
The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clinical isolates of 907 strains of Gram-positive bacteria, 1790 strains of Gram-negative bacteria, and 192 strains of anaerobic bacteria obtained from 30 medical institutions during 2004 was measured. The results were as follows; 1. MIC90 of MEPM for almost all of enterobacteriaceae and Haemophilus influenzae were 4-fold to 32-fold lower than those of other carbapenems. MEPM was more active than other carbapenem antibiotics against Gram-negative bacteria, especially against enterobacteriaceae and H. influenzae. MEPM were active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus. 2. As for Pseudomonas aeruginosa, imipenem (IPM) showed high cross-resistant rate againt meropenem-resistant P. aeruginosa (87.9%). MEPM showed low cross-resistant rate both againt IPM-resistant P. aeruginosa (49.2%) and ciprofloxacin-resistant P. aeruginosa (38.0%). 3. The proportion of extended-spectrum beta-lactamase (ESBL) strains was 3.1% (4 strains) in Escherichia coli, 8.0% (2 strains) in Citrobacter koseri, 2.5% (3 strains) in Klebsiella pneumoniae, 2.5% (2 strains) in Enterobacter cloacae, 0.9% (1 strains) in Serratia marcescens, and 2.2% (2 strains) in Proteus mirabilis. The proportion of metallo-beta-lactamase strains was 1.6% (5 strains) in P. aeruginosa. 4. Of all species tested, Peptostreptococcus spp. was the only species, which MIC90 of MEPM was more than 4-fold higher than that in our previous study using clinical isolates during 2002 (0.25 microg/ml --> 1 microg/ml). Therefore, there is almost no siginificant decrease in susceptibility of clinical isolates to meropenem. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem at present, 9 years after available for commercial use.
Yamaguchi
Keizo
K
Department of Microbiology and Infectious Diseases, Toho University School of Medicine.
Murakami
Masami
M
Takahashi
Ayako
A
Ishii
Yoshikazu
Y
Iwata
Morihiro
M
Itoh
Kouichi
K
Oohara
Tomoko
T
Watanabe
Naoki
N
Uehara
Nobuyuki
N
Nomura
Fumio
F
Watanabe
Masaharu
M
Yasujima
Minoru
M
Kasai
Takeshi
T
Kanno
Harushige
H
Aihara
Masanori
M
Suwabe
Akira
A
Yamahata
Kumiko
K
Maesaki
Shigefumi
S
Hashikita
Giichi
G
Kaku
Mitsuo
M
Kanemitsu
Keiji
K
Miyake
Kazunori
K
Oguri
Toyoko
T
Yoshida
Hiroshi
H
Nishiyama
Kyouko
K
Okada
Jun
J
Tazawa
Yoko
Y
Komatsu
Masaru
M
Nakashima
Hideki
H
Takemura
Hiromu
H
Kinoshita
Shohiro
S
Okada
Masahiko
M
Kobayashi
Sugako
S
Taminato
Tomohiko
T
Negayama
Kiyoshi
K
Horii
Toshinobu
T
Murase
Mitsuharu
M
Miyamoto
Hitoshi
H
Baba
Hisashi
H
Kusano
Nobuchika
N
Mihara
Eiichiro
E
Ishigo
Shiomi
S
Kambe
Masayuki
M
Itaha
Hideyuki
H
Fujita
Naohisa
N
Komori
Toshiaki
T
Ono
Junko
J
Yoshimura
Hisae
H
Ichiyama
Satoshi
S
Maeda
Shigetaka
S
Hirakata
Yoichi
Y
Matsuda
Junichi
J
Yamanaka
Kiyoharu
K
Mutara
Yoko
Y
Saikawa
Tetsunori
T
Hiramatsu
Kazufumi
K
Taminato
Shohiro
S
D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001421:Bacteria, Anaerobic / Q000187:drug effects*; D015780:Carbapenems / Q000494:pharmacology; D024881:Drug Resistance, Bacterial; D024901:Drug Resistance, Multiple, Bacterial; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D007275:Injections, Intravenous; D000077731:Meropenem; D013845:Thienamycins / Q000008:administration & dosage / Q000494:pharmacology*
D000890:Anti-Infective Agents; D015780:Carbapenems; D013845:Thienamycins; D000077731:Meropenem